What We're Reading: Page 156
Industry reads hand-picked by our editors
Jun 15, 2021
-
Axios
Health care CEO pay soars during pandemic
-
Bloomberg Law
Divisive Drug Patent Proposal From Trump Era Is on Biden Agenda
-
The Wall Street Journal
AstraZeneca Covid-19 Antibody Treatment Suffers Setback
Jun 14, 2021
-
The New York Times
What the C.E.O. of Pfizer and Other Covid-19 Fighters Learned From Their Parents
-
STAT
Alzheimer's Association blasts Biogen over price of new drug Aduhelm
-
Timmerman Report
Biotech Pride: 19 Industry Leaders Who Identify as LGBTQ
-
Health Affairs
The FDA’s Approval Of Aduhelm: Potential Implications Across A Wide Range Of Health Policy Issues And Stakeholders
Jun 11, 2021
-
POLITICO
Controversial drug approval stokes concern about lack of a permanent FDA chief
-
Associated Press
US extends expiration dates for J&J COVID vaccine by 6 weeks
-
STAT
Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s
-
Kaiser Health News
Change to Gilead Assistance Program Threatens PrEP Access, HIV Advocates Say
Jun 10, 2021
-
The Wall Street Journal
U.S. to Donate 500 Million Covid-19 Vaccine Doses to Lower-Income Countries
-
Bloomberg
Biogen Faces Democrats' Ire Over Price Tag for Alzheimer's Drug
-
The New York Times
What I Learned in 33 Years at the C.D.C.
-
FiercePharma
Regeneron's CEO, CSO pay under fire from advisory firms, who call on shareholders to oust a board member
Jun 09, 2021
-
STAT
Member of FDA's expert panel resigns over Alzheimer's therapy approval
-
Barron's
FDA Approves Pfizer's New Pneumococcal Vaccine, Setting Up Clash With Merck
-
C&EN
Kojin Therapeutics gets $60 million to explore ferroptosis inhibitors
-
Evaluate Vantage
Asco 2021 movers – PDS wins, but big pharma reigns
Jun 08, 2021
-
The Wall Street Journal
Millions of J&J Covid-19 Vaccines Are at Risk of Expiring in June
-
POLITICO
Biden to shore up supply chains for four sectors after 100-day reviews
-
Reuters
Pfizer to test COVID-19 vaccine in larger group of children below 12
-
FierceBiotech
Bayer's billion-dollar Parkinson's disease bets land in the clinic
Previous
